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Biallelic SZT2 Mutations Cause
Infantile Encephalopathy with Epilepsy
and Dysmorphic Corpus Callosum
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Epileptic encephalopathies are genetically heterogeneous severe disorders in which epileptic activity contributes to neurological
deterioration. We studied two unrelated children presenting with a distinctive early-onset epileptic encephalopathy characterized by
refractory epilepsy and absent developmental milestones, as well as thick and short corpus callosum and persistent cavum septum
pellucidum on brain MRI. Using whole-exome sequencing, we identified biallelic mutations in seizure threshold 2 (SZT2) in both
affected children. The causativemutations include a homozygous nonsensemutation and a nonsensemutation together with an exonic
splice-site mutation in a compound-heterozygous state. The latter mutation leads to exon skipping and premature termination of trans-
lation, as shown by RT-PCR in blood RNA of the affected boy. Thus, all three mutations are predicted to result in nonsense-mediated
mRNA decay and/or premature protein truncation and thereby loss of SZT2 function. Although the molecular role of the peroxisomal
protein SZT2 in neuronal excitability and brain development remains to be defined, Szt2 has been shown to influence seizure threshold
and epileptogenesis in mice, consistent with our findings in humans. We conclude that mutations in SZT2 cause a severe type of auto-
somal-recessive infantile encephalopathy with intractable seizures and distinct neuroradiological anomalies.Children presenting with neonatal or infantile encepha-
lopathies featuring epilepsy often follow a devastating
course leading to premature death or to a poor neurological
outcome. The developing brain seems to be particularly
prone and susceptible to seizure activity. The impairment
of active processes of myelination, synaptogenesis, neuron
migration, and apoptosis occurring in the neonatal and
infantile periods have been implicated in both the initia-
tion and the propagation of seizures, as well as in the often
devastating results of seizure activity.1,2 The motor, sen-
sory, and cognitive development of a child with epilepsy
is often impaired by ongoing epileptic activity.3 Thus, in
those conditions featuring frequent seizures and/or prom-
inent epileptiform abnormalities on electroencephalog-
raphy (EEG), epilepsy itself might contribute to cognitive
impairment, and these disorders are classified as epileptic
encephalopathies.
Early-onset epileptic encephalopathies (EOEEs) are high-
ly heterogeneous, and when the most common acquired,
malformative, and metabolic etiologies are ruled out, the
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onset, and the results of ancillary tests, and this has proved
useful for guiding genetic studies.4,5 However, the genetic
origins and underlying molecular processes of EOEEs
have been described in only a few well-defined syn-
dromes,5,6 such as Ohtahara syndrome (MIM 308350 and
612164). Ohtahara syndrome, one of the most severe
and earliest forms of epilepsy, is characterized by a suppres-
sion burst pattern on EEG and can be caused by heterozy-
gous de novo mutations in STXBP1 (MIM 602926).7,8
Mutations in more than ten additional genes cause early
infantile epileptic encephalopathy in a broad sense,6
but because of the lack of specific clinical, electrophysio-
logic, and neuroradiologic signs, many affected children
have no specific diagnosis. Contemporary tools for genetic
analysis, such as microarray-based comparative genomic
hybridization (array CGH) and whole-exome sequencing,
have greatly enhanced the ability to identify pathogenic
copy-number variations and mutations even in rare
disease phenotypes.9,10 Understanding the genetic basis
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Figure 1. Pedigrees and Pictures of Individuals with EOEE
(A and B) Pedigrees of family 1 (A) and family 2 (B). Individuals
affected or likely affected by EOEE are represented by filled black
and gray symbols, respectively. The index individuals are depicted
by arrows. The plus sign (þ) denotes the reference sequence, and
‘‘mut’’ indicates the respective mutation. Red ‘‘mut’’ represents
the c.73C>T (p.Arg25*) nonsensemutation, blue ‘‘mut’’ represents
the c.1496G>T exonic splice-site mutation, and green ‘‘mut’’ rep-
resents the c.2092C>T (p.Gln698*) nonsense mutation.
(C) Individual 1 at the age of 10 years (left) and individual 2 at the
age of 9 years (right). Common facial dysmorphic features include
a high forehead, downslanting palpebral fissures, ptosis, and
arched and laterally extended eyebrows.counseling, and classification of these diseases and might
eventually assist in the development of targeted treat-
ments.
We aimed at the identification of causative alleles in
genetically unresolved forms of EOEE. The study was
approved by the ethics committee of the University of
Ulm and the Helsinki committee of the Rabin Medical
Center in accordance with a protocol approved by the
National Committee for Genetic Studies, Israeli Ministry
of Health. Written informed consent to participate inThe Americanthe study was obtained from the affected individuals’
parents.
We studied two unrelated individuals with unexplained
EOEE and remarkable clinical and radiological similarities.
Clinical features are summarized in Table S1, available
online. Individual 1 (II:6, Figure 1A), a 10-year-old girl, is
the sixth child of healthy nonconsanguineous parents
who are both of Iraqi Jewish descent. One of her brothers
(individual II:5) was probably affected by the same condi-
tion; he died at age 3 years from respiratory infection,
and no DNA was available for genetic studies. Individual
2 (II:1, Figure 1B), a 9-year-old boy, is the first child of
healthy nonconsanguineous Spanish parents. Both unre-
lated children had common facial dysmorphic features
(Figure 1C), severe developmental delay with hypotonia
in infancy, decreased tendon reflexes, and absence of devel-
opmental milestones; there was no microcephaly. Seizures
began at the age of 4 years in individual 1 and at the age of
2 months in her affected brother and in individual 2.
Seizures in individual 1 were characterized by loss of con-
sciousness, drooling, and perioral cyanosis and were
at times followed by tonic-clonic generalization. Initially
described as focal, seizures in individual 2 affected either
side of the body with frequent tonic generalization. The
current seizure pattern includes multiple tonic seizures
per day and atypical absences. Seizures have proved highly
refractory to multiple antiepileptic drug combinations in
both children. EEG of individual 1 was normal prior to
epilepsy onset. After the onset of epilepsy, EEG showed
an abnormal background trace and prominent epilepti-
formabnormalities in both children (Figure S1), but no sup-
pression burst pattern. In individual 1, EEG at the age of 4
years showed slowed 4–5 Hz background activity with iso-
lated spike waves and sharp waves in the right frontopolar
and right frontocentral areas, as well as focal 12–14 and
6Hz epileptic activity with secondary generalization, corre-
sponding to clinical seizures. In individual 2, EEG at the age
of 8 years revealed altered background activity and no
topographic differentiation and multifocal spikes in either
hemisphere. Brain MRI showed a short and thick corpus
callosum and persistent cavum septum pellucidum in
both children, as well as in the deceased brother of individ-
ual 1 (Figure 2). Electromyography, nerve conduction ve-
locities, array CGH, and metabolic investigations in blood,
urine, and cerebrospinal fluid all gave normal results.
To identify the underlying genetic cause of the puta-
tively autosomal-recessive encephalopathy, we sequenced
the exomes of unrelated individuals 1 and 2. For the exome
sequence analysis, we used the SeqCap EZ Human Exome
Library v.2.0 and v.3.0 enrichment kits in individuals 1
and 2, respectively, and an Illumina HiSeq2000 sequencer
with a paired-end 100 bp protocol. Sequence reads were
aligned to the human reference genome (hg19 assembly,
UCSC Genome Browser). Mean coverage was 843 and
1113 for the exome of individuals 1 and 2, respectively,
and approximately 95% of the target sequences were
covered at least 103 in both exomes. Data analysis wasJournal of Human Genetics 93, 524–529, September 5, 2013 525
Figure 2. Brain MRI Findings
Persistent cavum septum pellucidum
(arrows) and thick and short corpus cal-
losum (arrowheads) in the three affected
children.
(A and E) Individual II-5 at the age of
6 months.
(B, C, F and G) Individual II-6 (individual
1) at the ages of 7 months (B and F) and
4 years and 8 months (C and G).
(D andH) Individual 2 at the age of 2 years.performed with a combination of available tools and
custom scripts (details are available on request) and, in
the case of individual 2, with the recently established
VARBANK exome pipeline from the Cologne Center for
Genomics (H.T. and P.N., unpublished data). We focused
on private and rare (minor allele frequency < 0.01) pre-
sumptively damaging variants.
Neither of the two exomes displayed an apparent patho-
genic allele in any of the 15 OMIM-referenced genes
mutated in early infantile epileptic encephalopathy.
Because the parents of individual 1 are both of Iraqi Jewish
origin, we assumed that a disease-causing mutation would
be present in the homozygous state. In individual 1, SNP-
array-based genotyping with an Affymetrix Human
Mapping 50K Xba 240 array and HomozygosityMapper11
identified five homozygosity regions > 2 Mb (on chromo-
somes 1, 3, 4, 10, and 12; Table S2); collectively, they span
20 Mb and contain >200 genes, none of which is known
to be implicated in EOEEs. Four genes mapping to these
regions of homozygosity contained a rare homozygous
variant (Tables S3 and S4). Only one of these genes,
SZT2, also harbored two distinct rare variants in individual
2, consistent with compound-heterozygous mutations.
SZT2 was the only gene in which rare or unique biallelic
damaging mutations were observed in the exomes of
both affected individuals.
We confirmed the three SZT2 (RefSeq accession number
NM_015284.3) mutations by Sanger sequencing on an
ABI3730 DNA Analyzer after PCR amplification of the
exons of interest. Individual 1 was homozygous for a
c.73C>T transition in exon 2. This mutation leads to a pre-
mature stop codon (p.Arg25*) (Figure 3A) and is predicted
to result in a truncation of SZT2 after 24 of 3,375 amino
acids and/or in nonsense-mediated mRNA decay (NMD).
Alternatively, Met50, the next downstream in-frame
methionine, might be used as a translation initiation
codon, leading to an N-terminally-shortened protein. The
c.73C>T nonsense mutation cosegregated with the
disease in the family (Figure 1A) and was absent from
143 Iraqi Jewish control subjects. Individual 2 was com-526 The American Journal of Human Genetics 93, 524–529, September 5, 2013pound heterozygous for a c.2092C>T
(p.Gln698*) nonsense mutation in-
herited from the mother and a pater-
nally inherited c.1496G>T mutation
(Figures 1B and 3B) that was predictedto lead to the amino acid substitution p.Ser499Ile. The
latter mutation affects the guanine at the last position of
exon 10 (Figure 3B) and is predicted by the NNSPLICE
and VARBANK-MaxEntScan splice prediction tools to
significantly weaken the exon 10 splice donor site
(NNSPLICE: splice score 0.88 for wild-type versus 0.11 for
the mutation; VARBANK-MaxEntScan: splice score 7.7 for
wild-type versus 1.36 for the mutation). For the splicing
analysis, total RNA from peripheral white blood cells of in-
dividual 2 and a control was extracted from fresh EDTA
blood by a standard trizol protocol. RT-PCR was performed
with the QIAGENOneStep RT-PCR kit with primers located
in SZT2 exons 9 and 11. Using direct sequencing of RT-PCR
products amplified from RNA of individual 2, we observed
skipping of exon 10 (Figure 3C), consistent with the bio-
informatic prediction. This out-of-frame exon-skipping
event is predicted to lead to a frameshift followed by a
premature termination codon (p.Gly412Alafs*86). Upon
RT-PCR, we detected the two mutations identified in
individual 2 in a heterozygous state with largely similar
intensity (Figure 3C and data not shown), suggesting
that—at least in blood—these mutations induce no or
incomplete NMD and are predicted to produce truncated
proteins. None of the three mutations identified in the
two children are present in the>6,000 European American
and African American individuals included in the
National Heart, Lung, and Blood Institute (NHLBI) Exome
Sequencing Project Exome Variant Server.
We have identified mutations in SZT2 as the cause of
EOEE in two unrelated children. The disease is character-
ized by severe developmental delay, refractory epilepsy,
and a thick corpus callosum and persistent cavum septum
pellucidum. Recent advances in molecular genetics are
leading to an expanding list of genes that are mutated in
EOEEs.6 Ideally, genetic testing should be guided by the
phenotype, but this is not possible for many EOEEs that
do not show distinctive clinical or radiological features in
addition to epilepsy and developmental delay. Thus, the
causative mutation remains unknown for most children
with allegedly genetic epileptic encephalopathy, which
Figure 3. SZT2 Mutations
(A) Homozygous nonsense mutation c.73C>T (p.Arg25*) detected
in individual 1.
(B) Compound-heterozygous mutation c.2092C>T (p.Gln698*)
(left) and c.1496G>T (right) identified in individual 2.
(C) RT-PCR on total RNA extracted from the blood of individual
2 and a control shows that the c.1496G>T exonic splice-site
mutation leads to the skipping of exon 10.poses additional difficulties for discussing prognosis and
genetic counseling. In contrast to the features of other
genetic EOEEs, a thick corpus callosum and persistent
cavum septum pellucidum appear as clues that should
raise the suspicion of SZT2 mutation.
Agenesis or dysgenesis of the corpus callosum is a rela-
tively frequent finding in neurodevelopmental disorders.
It has been described in several EOEE-associated Mende-The Americanlian syndromes, namely Aicardi syndrome (MIM 304050)
and the encephalopathy associated with mutations in
aristaless-related homeobox (ARX [MIM 300382 and
308350]).12 Thick corpus callosum has been described in
Cohen syndrome (MIM 216550), a disorder featuring
microcephaly, ocular abnormalities, and cognitive impair-
ment,13 and in interstitial 6q deletions.14 In most of the
cases, a relatively large corpus callosumhas been associated
with additional structural brain abnormalities.15 Another
neurodevelopmental syndrome with partial clinical over-
lap with the EOEE we describe is the genetically unresolved
syndrome of megalencephaly, mega corpus callosum, and
complete lack of motor development; this syndrome
might be associated with infantile spasms and persistent
cavum septum pellucidum.16,17
Whether SZT2 participates in the processes of cellular
proliferation, axonal growth, or glial patterning occurring
at the midline during development remains to be investi-
gated, and thus how mutations in SZT2 might influence
callosal and/or cortical morphogenesis is unknown. How-
ever, it is conceivable that defective axonal pruning might
have led to the thick corpus callosum. The finding of a
persistent cavum pellucidum has been associated with
epilepsy,18 but proof of causality is lacking and its fre-
quency in the general population is presently unknown.
Use of the term epileptic encephalopathy presupposes that
epilepsy itself contributes to encephalopathy. However, it
is often difficult to weigh the role of epilepsy in newborns
or infants against the pre-existing severe neurological
dysfunction, given that neither seizures nor electroen-
cephalographic abnormalities substantially modify a poor
outcome that is mainly explained by the underlying
etiology. The existence of severe developmental delay
antedating the onset of epilepsy and EEG abnormalities
in the affected girl suggests that mutations in SZT2 also
impair brain maturation and that this impairment occurs
independently of the seizures.
The 71-exon gene SZT2 (seizure threshold 2, previously
known as TIGR, C1orf84, and KIAA0467) encodes a large
protein of unknown function. It is widely expressed and
has high expression in the CNS in humans and mice,
predominantly in the parietal and frontal cortices, hippo-
campus, cerebellum, and dorsal root ganglia.19,20 SZT2
contains predicted functional domains, namely a superox-
ide dismutase motif and a PTS1 peroxisomal targeting
signal, and was shown to colocalize with catalase at the
peroxisome.19 In that study, a suppression-subtractive-
hybridization procedure was used for identifying upregu-
lation of SZT2 (called TIGR by the authors for ‘‘transcript
increased in glutamate resistance’’) as protective against
oxidative glutamate toxicity and H2O2-induced oxidative
stress in a neuronal cell model. Thus, oxidative glutamate
toxicity and excitotoxicity are plausible mechanisms un-
derlying epileptogenesis caused by SZT2 mutations.
Szt2 has been shown to influence seizure threshold
and epileptogenesis in mice. Szt2m1Frk-homozygous mouse
mutants are susceptible to induced seizures, although theyJournal of Human Genetics 93, 524–529, September 5, 2013 527
do not display spontaneous seizures.20 The Szt2m1Frk allele
contains a splice donor mutation after exon 32, predicting
transcriptional read-through, a translational frameshift,
and a premature stop. Male mutant mice treated daily
with a tetanic, high-frequency electrical stimulus devel-
oped seizures significantly earlier than did wild-type con-
trols. Most of the mice that were homozygous for another
mutation, Szt2Gt(XH662)By (a gene-trap mutation in exon
21), died before birth; surviving mutant mice had a low
seizure threshold.20 Thus, in mice, truncating mutations
in Szt2 can confer low seizure thresholds and embryonic
lethality, phenotypes consistent with the pharmacoresist-
ant seizures and developmental arrest in the human dis-
ease we describe. Unexpectedly, Szt2 mRNA levels were
upregulated rather than diminished in bothmutantmouse
models.20 Although the underlying pathomechanism
remains to be elucidated, the effect of the mutations at
the protein level might well be loss of function, as is sup-
posedly the case in the human disease.
Our study defines an infantile epileptic syndrome and
highlights an important role for SZT2 in epileptogenesis.
Severe developmental delay antedating the onset of epi-
lepsy suggests that SZT2 might also play a role in human
brain development. The identification of additional per-
sons with biallelic SZT2 mutations will shed further light
on the clinical spectrum of this emerging disorder.Supplemental Data
Supplemental Data include one figure and four tables and can be
found with this article online at http://www.cell.com/AJHG.Acknowledgments
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